Relay Therapeutics: A Precision Oncology Play Worth The Risk
Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...
pharmaphorum4 天
Eisai files biliary tract cancer drug tasurgratinib in Japan
Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...
ascopubs.org24 天
Tumor vascularity as a predictor of FGFR inhibitor response in FGFR2-fused intrahepatic ...
Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...
pharmaphorum2 天
Eisai debuts biliary tract cancer drug in Japan
It was approved by the MHLW on the strength of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable BTC that had previously ...